-
1Academic Journal
Συγγραφείς: E. O. Shchukina, V. A. Biryukov, O. B. Karyakin, S. А. Ivanov, Е. О. Щукина, В. А. Бирюков, О. Б. Карякин, С. А. Иванов
Πηγή: Cancer Urology; Том 20, № 3 (2024); 67-79 ; Онкоурология; Том 20, № 3 (2024); 67-79 ; 1996-1812 ; 1726-9776
Θεματικοί όροι: осложнения брахитерапии, high dose-rate brachytherapy, side effect of brachytherapy, brachytherapy complication, высокомощностная брахитерапия, побочные эффекты брахитерапии
Περιγραφή αρχείου: application/pdf
Relation: https://oncourology.abvpress.ru/oncur/article/view/1847/1558; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1541; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1542; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1543; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1544; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1545; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1546; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1547; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1549; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1550; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1551; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1552; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1553; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1554; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1847/1555; Злокачественные новообразования в России в 2022 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой, И.В. Лисичниковой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2023. 275 с.; Состояние онкологической помощи населению России в 2023 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 262 с.; Рак предстательной железы. Клинические рекомендации. Минздрав России, 2021.; NCCN Guidelines. Prostate Cancer. Version 1. 2023.; EAU Guidelines. Presented at the EAU Annual Congress, Milan, 2023.; Терапевтическая радиология: национальное руководство. Под ред. А.Д. Каприна, Ю.С. Мардынского. М.: ГЭОТАР-Медиа, 2019. 704 с.; Сычева И.В., Пасов В.В. Лучевые повреждения органов малого таза после лечения ранних стадий рака предстательной железы (обзор литературы). Радиация и риск 2014;23(4):99–115.; Li X., Fang D., Cooperberg M.R. et al. Long-term follow-up of International Prostate Symptom Score (IPSS) in men following prostate brachytherapy. World J Urol 2014;32(4):1061–6. DOI:10.1007/s00345-013-1188-y; Hamdy F.C., Donovan J.L., Lane J.A. et al.; ProtecT Study Group. Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2023;388(17):1547–58. DOI:10.1056/NEJMoa2214122; Suárez J.F., Zamora V., Garin O. et al. Mortality and biochemical recurrence after surgery, brachytherapy, or external radiotherapy for localized prostate cancer: a 10-year follow-up cohort study. Sci Rep 2022;12(1):12589. DOI:10.1038/s41598-022-16395-w; Donovan J.L., Hamdy F.C., Lane J.A. et al.; ProtecT Study Group. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer (Erratum in: N Engl J Med 2023;388(23):2208). N Engl J Med 2016;375(15):1425–37. DOI:10.1056/NEJMoa1606221; Kibel A.S., Ciezki J.P., Klein E.A. et al. Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specifc antigen era. J Urol 2012;187(4):1259–65. DOI:10.1016/j.juro.2011.11.084; Guo X.X., Xia H.R., Hou H.M. et al. Comparison of oncological outcomes between radical prostatectomy and radiotherapy by type of radiotherapy in elderly prostate cancer patients. Front Oncol 2021;11:708373. DOI:10.3389/fonc.2021.708373; Goy B.W., Burchette R., Soper M.S. et al. Ten-year treatment outcomes of radical prostatectomy vs external beam radiation therapy vs brachytherapy for 1503 patients with intermediate-risk prostate cancer. Urology 2020;136:180–9. DOI:10.1016/j.urology.2019.09.040; Cox J.D., Stetz J., Pajak T.F. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 1995;31(5):1341–6. DOI:10.1016/0360-3016(95)00060-C; Common Terminology Criteria for Adverse Events (CTCAE) v.5.0. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf; Yoshida K., Yamazaki H., Nakamara S. et al. Comparison of common terminology criteria for adverse events v3.0 and radiation therapy oncology group toxicity score system after high-dose-rate interstitial brachytherapy as monotherapy for prostate cancer. Anticancer Res 2014;34(4):2015–8. PMID: 24692740.; Matta R., Chapple C.R., Fisch M. et al. Pelvic complications after prostate cancer radiation therapy and their management: an international collaborative narrative review. Eur Urol 2018. DOI:10.1016/j.eururo.2018.12.003; Yu T., Zhang Q., Zheng T. et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One 2016;11:e0154499. DOI:10.1371/journal.pone.0154499; Viani G.A., Viana B.S., Martin J.E.C. et al. Intensity modulated radiotherapy reduces toxicity with similar biochemical control compared with 3-dimensional conformal radiotherapy for prostate cancer: a randomized clinical trial. Cancer 2016;122:2004–11. DOI:10.1002/cncr.29983; Zapatero A., Roch M., Büchser D. et al. Reduced late urinary toxicity with high-dose intensity-modulated radiotherapy using intraprostate fiducial markers for localized prostate cancer. Clin Transl Oncol 2017;19:1161–7. DOI:10.1007/s12094-017-1655-9; Mariados N., Sylvester J., Shah D. et al. Hydrogel spacer prospective multicenter randomized controlled pivotal trial: dosimetric and clinical effects of perirectal spacer application in men under going prostate image-guided intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 2015;92:971–7. DOI:10.1016/j.ijrobp.2015.04.030; Miralbell R., Roberts S.A., Zubizarreta E., Hendry J.H. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional data sets: a/b = 1.4 (0.9–2.2) Gy. Int J Radiat Oncol Biol Phys 2012;82:e17–24. DOI:10.1016/j.ijrobp.2010.10.075; Dearnaley D., Syndikus I., Mossop H. et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, noninferiority, phase 3 CHHiPtrial. Lancet Oncol 2016;17:1047–60. DOI:10.1016/S1470-2045(16)30102-4; Rodda S., Tyldesley S., Morris W.J. et al. ASCENDE-RT: ananalysis of treatment-related morbidity for a randomized trial comparing a low-dose-rate brachytherapy boost with a dose-escalated external beam boost for high- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2017;98:286–95. DOI:10.1016/j.ijrobp.2017.01.008; Hoskin P.J., Rojas A.M., Bownes P.J. et al. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localized prostate cancer. Radiother Oncol 2012;103:217–22. DOI:10.1016/j.radonc.2012.01.007; Willen B.D., Salari K., Zureick A.H. et al. High-dose-rate brachytherapy as monotherapy versus as boost in unfavorable intermediate-risk localized prostate cancer: a matched-pair analysis. Brachytherapy 2023:S1538-4721(23)00055-7. DOI:10.1016/j.brachy.2023.05.002; Martell K., Kollmeier M.A. Complications and side effects of high-dose-rate prostate brachytherapy. Brachytherapy 2021;20(5):966–75. DOI:10.1016/j.brachy.2020.10.007; Han B.H., Demel K.C., Wallner K. et al. Patient reported complications after prostate brachytherapy. J Urol 2001;166(3):953–7. PMID: 11490253.; Demanes D.J., Rodriguez R.R., Schour L. et al. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy’s 10-year results. Int J Radiat Oncol Biol Phys 2005;61:1306–16. DOI:10.1016/j.ijrobp.2004.08.01; https://oncourology.abvpress.ru/oncur/article/view/1847